Short-term combined treatment with exenatide and metformin for overweight/obese women with polycystic ovary syndrome

BACKGROUND: Obesity and insulin resistance (IR) are common features of polycystic ovary syndrome (PCOS). Metformin (MET) increases insulin sensitivity, but it is associated with unsatisfactory weight loss. The glucagon-like peptide-1 receptor agonist exenatide has been shown to reduce weight and IR...

Descripción completa

Detalles Bibliográficos
Autores principales: Ma, Rui-Lin, Deng, Yan, Wang, Yan-Fang, Zhu, Shi-Yang, Ding, Xue-Song, Sun, Ai-Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8667970/
https://www.ncbi.nlm.nih.gov/pubmed/34732660
http://dx.doi.org/10.1097/CM9.0000000000001712

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8667970/
https://www.ncbi.nlm.nih.gov/pubmed/34732660
http://dx.doi.org/10.1097/CM9.0000000000001712

Ejemplares similares